



HPTN Protocols Snapshot:

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HPTN 106	A Phase 2 Crossover Study Of On-Demand Prep Formulations Comparing Rectal And Oral Tenofovir-Based Prep Evaluating Extended Safety, Acceptability, And Pharmacokinetics/Pharmacodynamics	US	In Development	Y	PrEP	HIV Uninfected MSM	July 2024	July 2024	July 2025	Dec 2025	200	N/A
HPTN 104	To evaluate adherence to a single dual prevention pill, DPP (co-formulated TDF/FTC + ethinyl estradiol/levonorgestrel oral contraceptive pill (OCP), compared with the two tablets with daily oral TDF/FTC + ethinyl estradiol/levonorgestrel oral contraceptive pill for pre-exposure prophylaxis and pregnancy prevention in HIV-uninfected women	US	In Development	Y	MPT	HIV uninfected cis-women	Nov 2024	Nov 2024	Oct 2025	Oct 2026	1000	N/A
HPTN 113	Double Prevention: A Vanguard Study of an Integrated Strategy of HIV PrEP and STI PEP for Young Latino Sexual Minority Men (SMM) in the Americas.	US/INTL	Pending	N	Integrated Strategy	Young Latino Sexual Minority Men (SMM)	Dec 2024	Dec 2024	Dec 2025	Dec 2026	500	N/A

Updated: 16 April 2024

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HTPN 112	Improving HIV prevention among heterosexual men seeking STI services in sub-Saharan Africa: examining the feasibility, acceptability, and associated costs of a systems-navigator-delivered integrated prevention package.	INTL	Pending	N	Integrated Strategy	Heterosexual Men	Aug 2024	Aug 2024	May 2025	May 2025	215	N/A
A5416/HVTN 806/HPTN 108	A Phase I, Open-Label Study of the Safety, Antiviral & Immunomodulatory of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in sub-Saharan Africa Living with HIV during a Monitored Analytical Treatment Interruption	INTL	Pending	TBD	Antibody Mediated Prevention	Adult participants living with HIV	Apr 2024	Apr 2024	Nov 2024	Nov 2026	48	N/A
HVTN 141/HPTN 105	A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and in vitro neutralization of VRC01.23LS, ePGDM1400v9-LS and ePGT121v1-LS alone and in combination in healthy, HIV-uninfected adult participants	TBD	Pending	Y	PrEP	HIV Uninfected Adults	Dec 2024	Jan 2025	Mar 2025	Mar 2026	136	N/A

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HPTN 103	A Phase 2, Open-Label, Multicenter, Randomized Clinical Trial to Evaluate the Feasibility, Safety, and Acceptability of Long-Acting Subcutaneous Lenacapavir vs. Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis Among People who Inject Drugs	US	Pending	Y	PrEP	HIV Uninfected PWID	June 2024	June 2024	May 2025	Apr 2028	250	N/A
HPTN 102	A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability and Use of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis Among Women in the United States	US	Pending	Y	PrEP	HIV Uninfected Women	May 2024	May 2024	Dec 2024	June 2027	250	N/A
HPTN 096 Post Pilot	Getting to Zero among Black MSM in the American South: Testing the Efficacy of an Integrated Intervention Strategy	US	Pending	N	Integrated Strategy	Black MSM	Sept 2024	Sept 2024	TBD	2027	N/A	N/A

Updated: 16 April 2024

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HPTN 111	Uptake of HIV Self-testing and Linkage to Prevention and Care among Heterosexual Men attending Barbershops in Uganda: A Cluster Randomized Trial.	INTL	Enrolling	N	Integrated Strategy	Heterosexual Men	10 Mar 2024	13 Mar 2024	Aug 2024	May 2025	250	44
HPTN 107	A Phase II randomized, observer-blind, placebo-controlled study, to assess efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection.	US	Enrolling	Y	STI	Adults at risk of STI	19 Nov 2020	29 Dec 2020	TBD	TBD	2200	808
HPTN 084 Pregnancy	A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.	INTL	Enrolling	Y	PrEP	HIV-uninfected women	1 Jan 2022	1 Jan 2022	Sept 2024	Apr 2026	N/A	224
HVTN 804/HPTN 095	Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who received VRC01 or placebo and became HIV-infected during HVTN 704/HPTN 085	US/INTL	Closed to Accrual	N	Antibody Mediated Prevention	HIV-infected MSM and TGW	5 Feb 2020	8 Aug 2022	27 Jun 2023	June 2025	46	18

Updated: 16 April 2024

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HPTN 094	INTEGRA: A Vanguard Study of Integrated Strategies for Linking Persons with Opioid Use Disorder to Care and Prevention for Addiction, HIV, HCV and Primary Care	US	Closed to Accrual	N	Integrated Strategy	PWID	7 May 2021	2 June 2021	30 Sept 2023	Sept 2024	450	447
HVTN 805/HPTN 093	Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who received VRC01 or placebo and became HIV infected during HVTN 703/HPTN 081	INTL	Closed to Accrual	N	Antibody Mediated Prevention	HIV-infected women	02 Apr 2021	28 May 2021	14 Sept 2022	July 2025	61	13
HPTN 091	Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation to Prevent HIV Acquisition and HIV Transmission for Transgender Women in the Americas: A Vanguard Feasibility and Acceptability Study	US/INTL	Closed to Accrual	N	Integrated Strategy	Transgender Women	24 Feb 2021	26 Mar 2021	16 Dec 2022	Jun 2024	310	307
HPTN 084 OLE	A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.	INTL	Closed to Accrual	Y	PrEP	HIV-uninfected women	20 Jan 2022	20 Jan 2022	1 Oct 2022	Jan 2026	n/a	2472

Updated: 16 April 2024

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HPTN 083 OLE	A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men	US/INTL	Closed to Accrual	Y	PrEP	HIV-uninfected MSM and TGW	5 Dec 2016	19 Dec 2016	16 Mar 2020	Sept 2024	N/A	2278
HPTN 083	A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men	US/INTL	Closed to Accrual	Y	PrEP	HIV-uninfected MSM and TGW	5 Dec 2016	19 Dec 2016	16 Mar 2020	Mar 2024	5000	4570
HVTN 140/HPTN 101	A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants	US/INTL	Closed to Follow Up	Y	Antibody Mediated Prevention	HIV Uninfected Adults	20 Oct 2021	15 Nov 2021	5 Oct 2022	19 July 2023	95	95

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HVTN 136/ HPTN 092	A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous infusion or via subcutaneous injections in healthy, HIV-uninfected adult participants	US	Closed to Follow-Up	Y	Antibody Mediated Prevention	HIV-uninfected adults	24 Aug 2020	10 Nov 2020	05 Oct 2021	18 Jan 2023	32	33
HVTN 130/HPTN 089	A Phase I clinical trial to evaluate the safety, pharmacokinetics, and functional activity of a combination of VRC07-523LS, PGT121, and PGDM1400 in healthy, HIV-1 uninfected adult participants.	US	Closed to Follow-Up	Y	Antibody mediated prevention	HIV-uninfected adults	17 July 2019	31 Jul 2019	17 Dec 2019	25 Mar 2021	27	27
HPTN 084-01	Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Females – A Sub-study of HPTN 084	INTL	Closed to Follow-Up	Y	PrEP	HIV-uninfected adolescents	4 Nov 2020	3 Dec 2020	6 Aug 2021	10 Jan 2023	55	55

Updated: 16 April 2024

Protocol #	Title	Sites	Study Status	IND	Research Area	Study Population	Open to Accrual (projected)	1 st Participant Enrolled (projected)	Closed to Accrual (projected)	Closed to Follow Up (projected)	Target Accrual	Actual Accrual as of report date
HPTN 083-01	Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Males – A sub-study of HPTN 083	US	Closed to Follow Up	Y	PrEP	HIV-uninfected adolescents	19 Feb 2020	6 July 2020	10 Jan 2022	7 July 2023	55	9
HPTN 084 Blinded	A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.	INTL	Participants of Study/Primary Analysis Complete	Y	PrEP	HIV-uninfected women	7 Nov 2017	27 Nov 2017	8 Nov 2020	17 Oct 2022	3200	3224